Among the most resistant forms of breast cancer, triple-negative tumors carrying TP53 mutations have long confounded oncologists — particularly when the LIG1 gene is lost, rendering platinum chemotherapy ineffective. Researchers at Baylor College of Medicine have now turned that genetic vulnerability on itself, discovering that combining two DNA repair inhibitors, olaparib and ceralasertib, can trap these cells in a state they cannot survive. The work, grounded in mechanistic precision rather than trial and error, offers a rational path forward for patients who have exhausted conventional opti
Researchers identify drug combo to overcome chemotherapy resistance in aggressive breast cancer
Triple-negative breast cancer patients with TP53 mutations and LIG1 loss currently face chemotherapy resistance, limiting treatment options for this aggressive cancer subtype.